Nottem (Zolpidem Tartrate)

Zolpidem Tartrate, the active ingredient in Nottem, is a non‑benzodiazepine hypnotic (Z‑drug) presented as an oral dosage form for oral use. It is indicated for the short‑term treatment of insomnia, particularly difficulty initiating sleep, in adult patients.

GNH USA supplies Nottem as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zolpidem Tartrate belongs to the non‑benzodiazepine hypnotic class and is used to manage sleep‑related disorders. - Insomnia (difficulty initiating sleep): helps patients fall asleep more quickly. - Short‑term insomnia: provides temporary relief of sleep onset problems for up to four weeks. - Sleep‑onset insomnia: improves the ability to start sleeping after going to bed.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Drowsiness or excessive daytime sleepiness - Dizziness or light‑headedness - Headache - Unpleasant taste or dry mouth - Nausea or gastrointestinal discomfort - Short‑term memory impairment

Serious or Rare Side Effects: - Complex sleep behaviors such as sleepwalking or driving while asleep - Allergic reactions including rash, itching, or swelling - Depression or emergence of suicidal thoughts - Respiratory depression, especially when combined with other CNS depressants - Severe hypotension or cardiovascular events - Hallucinations or psychotic symptoms

Before prescribing Zolpidem Tartrate, clinicians should consider several safety measures. - Assess sleep history: confirm that insomnia is appropriate for short‑term pharmacologic therapy. - Avoid alcohol: concurrent use can intensify sedative effects and impair judgment. - Use caution in hepatic impairment: reduced metabolism may increase drug exposure. - Monitor for complex sleep behaviors: educate patients to report unusual activities performed while not fully awake. - Review concomitant CNS depressants: adjust therapy when used with opioids or benzodiazepines. - Store at ambient temperature: keep in the original packaging, protect from moisture and direct sunlight.

Zolpidem Tartrate can interact with several other medicines, influencing its safety and efficacy.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Opioids (e.g., oxycodone, morphine): combined use can cause profound respiratory depression. - Other CNS depressants (e.g., benzodiazepines, barbiturates): additive sedative effects increase risk of overdose.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels. - Selective serotonin reuptake inhibitors (SSRIs) and other antidepressants: may enhance sedation. - Antihistamines and over‑the‑counter sleep aids: monitor for cumulative drowsiness. - Alcohol: even moderate intake can potentiate sedative action.